IP Verse

Fluticasone Furoate In The Treatment Of Copd - EP3148521

The patent EP3148521 was granted to Glaxosmithkline on Dec 18, 2019. The application was originally filed on May 27, 2015 under application number EP15726106A. The patent is currently recorded with a legal status of "Revoked".

EP3148521

GLAXOSMITHKLINE
Application Number
EP15726106A
Filing Date
May 27, 2015
Status
Revoked
May 19, 2025
Publication Date
Dec 18, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GILL JENNINGS & EVERYSep 16, 2020GILL JENNINGS & EVERYADMISSIBLE
TEVA PHARMACEUTICALSSep 8, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONGB2242134
DESCRIPTIONUS2007062525
DESCRIPTIONUS2008196718
DESCRIPTIONUS2012309725
DESCRIPTIONUS5873360
DESCRIPTIONUS7101866
DESCRIPTIONUS7488827
DESCRIPTIONUS8534281
DESCRIPTIONUSRE44874E
DESCRIPTIONWO0212265
DESCRIPTIONWO03024439
DESCRIPTIONWO03061743
DESCRIPTIONWO2005104745
DESCRIPTIONWO2007012871
DESCRIPTIONWO2007068896
DESCRIPTIONWO2011067212
DESCRIPTIONWO2014027045
INTERNATIONAL-SEARCH-REPORTWO2011067212
OPPOSITIONWO2011067212
OPPOSITIONWO2012168161

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- NEIL C. BARNES ET AL, "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", EUROPEAN RESPIRATORY JOURNAL, (20160225), vol. 47, no. 5, doi:10.1183/13993003.01370-2015, ISSN 0903-1936, pages 1374 - 1382, XP055522832
OPPOSITION- Anonymous, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) FOR ORAL INHALATION USE", BREO ELLIPTA Leaflet, (20130000), pages 1 - 41, XP055736888
OPPOSITION- Donald P Tashkin, Charlie Strange, "Inhaled Corticosteroids Are Beneficial in Chronic Obstructive Pulmonary Disease", American Journal of Respiratory and Critical Care Medicine, (20000000), vol. 161, pages 341 - 344, XP055737179
OPPOSITION- Ekaterina S Gladysheva , Atul Malhotra, Robert L Owens, "Influencing the decline of lung function in COPD: use of pharmacotherapy", International Journal of COPD, (20100000), vol. 5, pages 153 - 164, XP055737093
OPPOSITION- GOLD, "Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease", Global Initiative for Chronic Obstructive Disease, (20130000), XP055736139
OPPOSITION- Jørgen Vestbo, Et Al., "Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disaese", (20130000), pages 1 - 99, XP055736917
OPPOSITION- Woods Andrew J., James S Wheeler , Christopher K Finch , Nathan A Pinner, "Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease", INTERNATIONAL JOURNAL OF COPD, (20140000), vol. 9, pages 421 - 430, XP055737215
OPPOSITION- Wouters, EFM., Postma, DS., Hop, WCJ., Prins, J., Kuipers, AF., Pasma, HR., Hensing, CAJ., Creutzberg, EC., "Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial", Thorax, (20050000), vol. 60, pages 480 - 487, XP027821314
OPPOSITION- J Y Lacoste , J Bousquet, P Chanez, T Van Vyve, J Simony-Lafontaine, N Lequeu, P Vic, I Enander, P Godard, F B Michel, "EOSINOPHILIC AND NEUTROPHILIC INFLAMMATION IN ASTHAM, CHRONIC BRONCHITIS, AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE", J. Allergy Clin Immunol, (19930000), vol. 92, pages 537 - 548, XP009070364
OPPOSITION- Jose Luis Izquierdo Alonso; Jos Miguel Rodrguez Glez-Moro, "The Excessive Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease", Arch Bronconeumol., (20120000), vol. 48, no. 6, pages 207 - 212, XP028485820
OPPOSITION- F.J. MARTINEZ et al., "Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: A randomised trial", Respiratory Medicine, (20130000), vol. 107, doi:10.1016/j.rmed.2012.12.016, pages 550 - 559, XP029004010
OPPOSITION- Martinez Fernando J; Boscia Joseph; Feldman Gregory; Scott-Wilson Catherine; Kilbride Sally; Fabbri Leonardo; Crim Courtney; Calverley Peter M A, "Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial", Respiratory Medicine, (20130401), vol. 107, no. 4, pages 550 - 559, XP029004010
OPPOSITION- M.T. DRANSFIELD et al., "Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials", Lancet Respir Med, (20130000), vol. 1, pages 21 0 - 223, XP055736138
OPPOSITION- S. PASCOE et al., "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials", Lancet Respiratory Medicine, (20150000), vol. 3, pages 4 35 - 442, XP008177095
OPPOSITION- P.S. BURGE et al., "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial", British Medical Journal, (20000000), vol. 320, doi:10.1136/bmj.320.7245.1297, pages 1297 - 1303, XP055522775
OPPOSITION- G C Donaldson, T A R Seemungal, A Bhowmik, J A Wedzicha, "Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease", Thorax, (20020000), vol. 57, pages 847 - 852, XP055737075
OPPOSITION- C.E. BRIGHTLING et al., "Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease", Thorax, (20050000), vol. 60, pages 193 - 198, XP055736134
OPPOSITION- P. M. TWEEDALE et al., "Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects", Thorax, (19870000), vol. 42, pages 487 - 490, XP055736129
OPPOSITION- Meijer R., H Kerstjens, L Arends, H Kauffman, G Koeter, And D Postma, "Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma", Thorax, (19990000), vol. 54, pages 894 - 899, XP055737122
OPPOSITION- Mona Bafadhel; Susan Mckenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret Mccormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling, "Acute exacerbations of COPD: identification of biological clusters and their Biomarkers", American Journal of Respiratory and Critical Care Medicine, (20110616), vol. 184, no. 6, pages 662 - 671, XP055205020
OPPOSITION- M. BAFADHEL et al., "Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease", American Journal of Respiratory and Critical Care Medicine, (20120000), vol. 186, doi:10.1164/rccm.201108-1553OC, pages 48 - 55, XP055204840
OPPOSITION- Mona Bafadhel; Susan Mckenna; Sarah Terry; Vijay Mistry; Mitesh Pancholi; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling, "Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial", AJRCCM, (20120323), vol. 186, no. 1, pages 48 - 55, XP055204840
OPPOSITION- Jørgen Vestbo , Suzanne S. Hurd , Alvar G. Agustí , Paul W. Jones , Claus Vogelmeier , Antonio Anzueto , Peter J. Barnes , Leonardo M. Fabbri , Fernando J. Martinez , Masaharu Nishimura , Robert A. Stockley , Don D. Sin , and Roberto Rodriguez-Roisin, "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease", Am J Respir Crit Care Med, (20130215), vol. 187, no. 4, pages 347 - 365, XP055736897
OPPOSITION- R. TRIVEDI et al., "Umeclidinium in patients with COPD: a randomised, placebo-controlled study", Eur Respir J, (20140000), vol. 43, pages 72 - 81, XP055736143
OPPOSITION- Jones P W , L R Willits, P S Burge, P M A Calverley, "Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations", Eur Respir J, (20030000), vol. 21, pages 68 - 73, XP055737114
OPPOSITION- N. BARNES et al., "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", European Respiratory Journal, (20160000), vol. 47, doi:10.1183/13993003.01370-2015, pages 1374 - 1382, XP055522832
OPPOSITION- A. MATHIOUDAKIS et al., "Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids", European Respiratory Journal, (20180000), vol. 52, no. 62, page OA 2125, XP055736132
OPPOSITION- Jeremy A Falk, Omar A Minai, Zab Mosenifar, "Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease", Proc Am Thorac Soc, (20080000), vol. 5, pages 506 - 512, XP055736976

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents